Activation of WNT/Beta-Catenin Signaling and Regulation of the Farnesoid X Receptor/Beta-Catenin Complex After Murine Bile Duct Ligation.


Journal

Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 06 07 2019
accepted: 29 08 2019
entrez: 14 12 2019
pubmed: 14 12 2019
medline: 14 12 2019
Statut: epublish

Résumé

We have recently shown that loss of β-catenin prevents the development of cholestatic liver injury and fibrosis after bile duct ligation (BDL) due to loss of the inhibitory farnesoid X receptor (FXR)/β-catenin complex, which results in decreased hepatic bile acids (BAs) through activation of FXR. To further understand the role of Wnt/β-catenin signaling in regulating BA metabolism and cholestasis, we performed BDL on mice in which hepatocyte Wnt signaling is deficient but β-catenin is intact (low-density lipoprotein receptor-related protein [LRP]5/6 knockout [DKO]) as well as mice that have enhanced hepatocyte β-catenin expression (serine 45 mutated to aspartic acid [S45D] transgenic [TG] mice). Despite decreased biliary injury after BDL, hepatic injury, fibrosis, and inflammation were comparable in DKO and wild-type (WT) mice. Notably, the FXR/β-catenin complex was maintained in DKO livers after BDL, coincident with significantly elevated hepatic BA levels. Similarly, TG mice did not display accelerated injury or increased mortality despite overexpression of β-catenin. There was no augmentation of FXR/β-catenin association in TG livers; this resulted in equivalent hepatic BAs in WT and TG mice after BDL. Finally, we analyzed the effect of BDL on β-catenin activity and identified an increase in periportal cytoplasmic stabilization and association with T-cell factor 4 that correlated with increased expression of distinct downstream target genes.

Identifiants

pubmed: 31832572
doi: 10.1002/hep4.1430
pii: HEP41430
pmc: PMC6887668
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1642-1655

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK120531
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK103775
Pays : United States
Organisme : NIBIB NIH HHS
ID : T32 EB001026
Pays : United States

Informations de copyright

© 2019 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.

Références

Annu Rev Pathol. 2018 Jan 24;13:351-378
pubmed: 29125798
Hepatology. 2018 Mar;67(3):955-971
pubmed: 28714273
Nature. 2007 Jul 19;448(7151):313-7
pubmed: 17554338
Stem Cells. 2011 Sep;29(9):1362-70
pubmed: 21732496
Gastroenterology. 1999 Sep;117(3):669-77
pubmed: 10464144
Gastroenterology. 2015 Jun;148(7):1294-310
pubmed: 25747274
Development. 2004 Jul;131(13):3069-80
pubmed: 15163629
Hepatology. 2014 Sep;60(3):964-76
pubmed: 24700412
Am J Pathol. 2010 Feb;176(2):744-53
pubmed: 20019186
Gastroenterology. 1999 Jan;116(1):179-86
pubmed: 9869616
Gastroenterology. 1991 Jan;100(1):203-11
pubmed: 1983822
Hepatology. 2014 Jun;59(6):2344-57
pubmed: 24214913
Hepatology. 2016 Nov;64(5):1652-1666
pubmed: 27533619
Br J Exp Pathol. 1976 Feb;57(1):85-94
pubmed: 1268043
J Clin Invest. 2003 Dec;112(11):1678-87
pubmed: 14623915
Hepatology. 2010 May;51(5):1603-13
pubmed: 20432254
Gene Expr. 2014;16(2):51-62
pubmed: 24801166
Gastroenterology. 1990 Aug;99(2):466-77
pubmed: 1694804
Clin Pharmacol Ther. 2012 Nov;92(5):599-612
pubmed: 22948894
Hepatology. 2007 May;45(5):1298-305
pubmed: 17464972
J Pharmacol Exp Ther. 2005 May;313(2):604-12
pubmed: 15644430
Br J Surg. 2008 May;95(5):646-56
pubmed: 18196571
JCI Insight. 2017 Mar 9;2(5):e90780
pubmed: 28289714
Oncogene. 2005 May 19;24(22):3619-31
pubmed: 15782138
Development. 2013 Feb 1;140(3):639-48
pubmed: 23293295
Development. 2013 Aug;140(15):3128-38
pubmed: 23824574
J Hepatol. 2007 Mar;46(3):365-71
pubmed: 17223219
Hepatology. 2001 Mar;33(3):616-26
pubmed: 11230742
J Hepatol. 2004 Mar;40(3):539-51
pubmed: 15123373
EMBO J. 2000 Apr 17;19(8):1839-50
pubmed: 10775268
Gastroenterology. 2006 Nov;131(5):1561-72
pubmed: 17101329
Hepatology. 2010 Apr;51(4):1410-9
pubmed: 20091679
Hepatology. 2010 Oct;52(4):1410-9
pubmed: 20722001
Mol Cell. 2000 Sep;6(3):517-26
pubmed: 11030332

Auteurs

Rong Zhang (R)

Department of Pathology University of Pittsburgh Pittsburgh PA.

Toshimasa Nakao (T)

Department of Drug Discovery Medicine Kyoto Prefectural University of Medicine Kyoto Japan.

Jing Luo (J)

Department of Surgery University of Pittsburgh Pittsburgh PA.

Yuhua Xue (Y)

Department of Pathology University of Pittsburgh Pittsburgh PA.

Pamela Cornuet (P)

Department of Pathology University of Pittsburgh Pittsburgh PA.

Michael Oertel (M)

Department of Pathology University of Pittsburgh Pittsburgh PA.

Karis Kosar (K)

Department of Pathology University of Pittsburgh Pittsburgh PA.

Sucha Singh (S)

Department of Pathology University of Pittsburgh Pittsburgh PA.

Kari Nejak-Bowen (K)

Department of Pathology University of Pittsburgh Pittsburgh PA.
Pittsburgh Liver Research Center University of Pittsburgh Pittsburgh PA.

Classifications MeSH